Anavex Life Sciences Corp (AVXL)

[Anshu2]

Too much to write .. but the short story is: AVXL's CEO picked the endpoint measures that suited him/trial, and reported success based on that. That kills any notion of trial success. Moreover, the endpoint measures he picked (odd-ratios) have perhaps/likely minimal relevance to "meaningful clinical benefit".